Bristol-Myers Squibb Co.

  • A Trio of Cancer Immunotherapy Innovators

    By Seth Robey - June 14, 2013 | Tickers: BMY, CLDX, IMGN, RHHBY, SGEN

    The cancer world has been abuzz after an exciting ASCO conference.  Bristol-Myer's Squibb (NYSE: BMY) presented really promising updates for its PD-1 inhibitor nivolumab in late-stage melanoma, leading one Citigroup analyst to declare "the beginning of the end of cancer."  With Merck and Roche (NASDAQOTH: RHHBY) also boasting PD-1 inhibitors we can only hope someone has a magic bullet.  But is there space in this massive market for the more »

  • Is Pfizer a Buy?

    By Bob Ciura - June 11, 2013 | Tickers: BMY, LLY, PFE

    The biggest pharmaceutical companies in the United States are in an enviable position. They sell products that are literally a matter of life and death. People who take medication will pay for it no matter what, and will often cut back on many other necessary expenses if need be.

    As a result it should be no surprise that some of the market’s best performers last year came from the more »

  • A Promising Platform for Cancer Immunotherapy

    By Seth Robey - June 10, 2013 | Tickers: BMY, CLDX, DNDN, MRK

    A 2011 Nobel Prize in Physiology and Medicine is certainly impressive.  Using a novel cancer treatment on yourself is both impressive and courageous.  Dr. Ralph Steinman believed so enthusiastically in the cancer vaccines which he helped to develop that he used many of them to treat his own pancreatic cancer.  Surviving for five additional years, Steinman was able to use his position on the Scientific Advisory Board of Celldex (NASDAQ: CLDXmore »)

  • ASCO Stocks That Should Sizzle in the Future

    By Terry Chrisomalis - June 9, 2013 | Tickers: BMY, CLVS, MRK

    Every year, there is a big event for pharmaceutical companies known as ASCO. ASCO is the American Society Of Clinical Oncology, in which pharmaceutical companies post results on cancer trials. There were many companies that posted amazing results this time, but here, I will highlight three of them which will might be good for your portfolio in the long-term. The three pharmaceutical stocks to own for the long run are more »

  • Billionaire Jim Simons' Buy Ups

    By Marshall Hargrave - June 7, 2013 | Tickers: BMY, LLY, GOOG, IBM

    Billionaire Jim Simons founded Renaissance Technologies ("RenTech"), his private investment firm, in 1982. Simons is renowned for his Medallion Fund, which made Simons one of the richest people in the world. Basically, the Medallion Fund employs high-frequency trading and exploits inefficiencies in the stock market. The expenses are high for the fund; it charges a 5% fixed fee, while also charging a 44% performance fee. Currently the fund’s investors more »

  • 3 Noteworthy Upgrades Worth a Look

    By Brian Nichols - June 5, 2013 | Tickers: BMY, INTC, SODA

    Intel (NASDAQ: INTC) traded higher after last weekend’s feature story in Barron’s. The firm upped its outlook, saying it expects Intel to double over the next five years due to market share gains in tablets and smartphones.

    Moreover, Barron’s feature columnist Jack Hough anticipates big demand for lucrative server chips and a stabilization in the PC market. Hough also expects the company to cut its capital spending more »

  • This Pharma Company Is Making the Right Moves

    By Arturo Cuevas - June 3, 2013 | Tickers: AZN, BMY, OMTH

    Editor's Note: This article has been amended to better reflect the Amylin deal.

    Mergers and acquisitions appear to be continuously reshaping the pharmaceuticals industry. One of the latest initiatives involved British drug maker AstraZeneca (NYSE: AZN), which announced this May 28 that a definitive agreement has been reached for its acquisition of Princeton, NJ-based Omthera Pharmaceuticals (NASDAQ: OMTH).

    Notably, this development came just a month after Omthera’s IPO more »

  • 3 Stocks to Watch Ahead of ASCO

    By Brian Nichols - May 28, 2013 | Tickers: BMY, GILD, HALO

    At the annual ASCO meeting in Chicago, thousands of health-care researchers and professionals unite to advance cancer treatment. This year's meeting takes place next weekend, and its presentations will be important not only to those who work in cancer research, but also to Wall Street. Here are three promising stocks I'll be watching closely as the conference unfolds.

    New Age Of Immune-Suppressing Agents Under The Microscope

    Dendreon’s more »

  • The New Drug Can Make This Stock a Steal

    By Tanya Kanodia - May 23, 2013 | Tickers: BMY, MRK, RHHBY

    Bristol-Myers Squibb (NYSE: BMY) has developed hit drugs for the company and has a well structured R&D program with highly efficient and motivated workforce. The company has taken a hit in the recent times due to patent losses of some of its drugs which led to a loss in profitability. However, Bristol-Myers Squibb has several upcoming drugs in its pipeline which makes it a good long term investment. Here more »

  • Four Stocks to Own Regardless of a Pullback

    By John Timmes - May 16, 2013 | Tickers: BMY, GIS, MCD, VZ

    As the chatter surrounding a market pullback continues to build, these companies remain good investments.  We look at fours stocks in four different sectors that meet the below criteria.

    Evaluation Criteria

    Dividend Yield

    One of the major components of any sound buy-and-hold stock portfolio should be dividend yield.  A strong dividend suggests a company is financially solid and generating sufficient cash flow to maintain all business operations.  Dividend yield will more »

  • This Sector Is No Bargain

    By Bob Ciura - May 15, 2013 | Tickers: BMY, LLY, PFE

    Many stocks within the pharmaceutical industry have rallied significantly over the past few years and now sit at multi-year highs. It’s not hard to understand why: in today’s investing environment of historically low interest rates, bank products like certificates of deposit pay little to no interest. The 10-Year Treasury Bond still yields less than 2%, so high-quality equities like these stocks that provide yields in excess of 3 more »

  • Why This Pharma Giant Doesn't Look Good Now

    By Sonam Chamaria - May 14, 2013 | Tickers: BMY, MRK, PFE

    Pharmaceutical companies in the U.S. are not having it easy these days. When Johnson & Johnson reported its latest numbers recently, it suffered from currency headwinds. Last week, Merck (NYSE: MRK) announced its first-quarter earnings, managing to beat analyst estimates. Is it stronger than the rest? Or is it in the same boat? Let's find out.

    Going down

    In the previous quarter, Merck's global sales amounted to $10 more »

  • Buying the Pharma Dips

    By Marshall Hargrave - May 13, 2013 | Tickers: BMY, MRK, PFE

    Pfizer (NYSE: PFE) saw a strong pullback earlier this month, with its stock tumbling over 6% after reporting first-quarter earnings results. Meanwhile, fellow drug maker Merck (NYSE: MRK) was down over 4% for similar reasons. Does this present investors with a buying opportunity? Quite possibly so; however, not all drug makers are created equally.
    After the pullback, Pfizer trades at 12.3 times forward earnings and Merck at 12 times more »
  • 6 Big Pharma Stocks With Lower Credit Risk Than U.S. Treasuries: Part I

    By Meena Krishnamsetty - May 10, 2013 | Tickers: BMY, LLY, JNJ

    The healthcare sector has been known for paying dependable dividends and producing strong total returns over time. Among the major pharmaceutical companies, there are a few that stand out as most financially sound, as reflected by their CDS spreads below those of the U.S. Treasuries.

    Why use CDS spreads?

    A credit default swap is essentially like a form of insurance, that two parties can swap between one another for more »

  • Are Dividend Yields the Cure for Pharma Investors' Woes?

    By Nauman Aly - April 30, 2013 | Tickers: BMY, LLY, GSK

    As the market continues to climb, investors are beginning to see thinning dividend yields on many of their big pharma shares. But by sticking with quality - and with companies that are keeping their product pipelines full with new drugs - one can certainly find the key to not just share growth but also a nice steady income along the way.

    Keeping yields healthy

    One of the higher yielding big pharmaceutical companies more »

  • Merck's Product Pipeline Could Lead To Healthy Shareholder Returns

    By Nauman Aly - April 27, 2013 | Tickers: BMY, MRK, PFE

    In the big pharma sector, it can oftentimes be hit or miss when seeking the next big growth stock. Yet, while it may be difficult to predict what company will produce "the next big thing," there is something to be said about riding price up slowly while cashing in on dividends along the way. One stock opportunity that could provide a steady stream of dividend income is Merck (NYSE: MRKmore »)

  • "The Most Sustainable Company in the World"

    By Tyler Wofford - April 25, 2013 | Tickers: BMY, LLY, MDT, NVO

    In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their list. I was surprised that it wasn't a company like Apple, but rather a company in the pharmaceutical industry. As a type 1 diabetic, I understand the costs that go along with the disease. However, even I was surprised to see a company more »

  • Alzheimer’s Milkshakes and the Growth of Medical Nutrition

    By Matthew Luke - April 22, 2013 | Tickers: ABT, ABBV, BMY, DANOY.PK, MJN, NSRGY, PFE

    A milkshake is not foremost on most people’s list of treatments for the neurological disorder Alzheimer’s. But a milkshake is indeed one treatment for those with early-stage Alzheimer’s disease, thanks to the recent United Kingdom release of Souvenaid. This milkshake and similar products are some of the many treatment options in an emerging hybridization of food and medicine.

    Defining a Milkshake
    By “milkshake” I of course do more »

  • Drug Stocks on Citi's Dividend Buy List

    By Reuben Brewer - April 21, 2013 | Tickers: BMY, MRK, PFE

    Barron's recently posted Citi's updated list of large, financially strong, high-yielding, dividend-paying companies. Three drug companies make the grade: Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Bristol-Myers Squibb (NYSE: BMY).

    The Citi list

    Every month, Citi creates a list of recommended companies with big yields. The list leans toward the large side of the market, with a minimum market cap of $10 billion required to pass the screen more »

  • Bristol-Myers Squibb: Growing Bigger and Better

    By Shas Dey - April 19, 2013 | Tickers: AZN, BMY, MRK

    Bristol-Myers Squibb (NYSE: BMY) has been in the spotlight for its so-called “desired” acquisitions and its size issues, along with patent expiration news. Analysts have been debating the company's decision to expand and acquire companies in the face of declining revenue, wondering whether it makes sense to focus on product pipeline or growing bigger. I believe Bristol-Myers isn't looking at acquisitions apart from its product pipeline strategy. It more »

  • Page 2 of 10